?-To The Moon - Tiger Brokers Online Investing Community - To The Moon

2
Comment
Favorite

披着牛皮的雷熊
2021-07-17

?

American COVID-19 vaccine manufacturer Moderna successfully entered the bid, and its stock price rose nearly 9% during the session

截止发稿，Moderna股价周五早盘大涨近9%，至每股283美元，创下历史新高，这将使该股今年迄今的涨幅扩大至165%左右，市值约为1120亿美元。此前，部分分析人士曾对Moderna的股价飙升表示担忧。此前，Moderna在5月6日公布了强于预期的第一季度每股收益2.84美元，营收增至19亿美元。Moderna当时表示，在一项针对12至17岁青少年的研究中，该公司的新冠疫苗100%有效。Moderna透露，其针对青少年的新冠疫苗2、3期研究覆盖了3732名年龄在12至18岁以下的受试者。

American COVID-19 vaccine manufacturer Moderna successfully entered the bid, and its stock price rose nearly 9% during the session

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

2

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":179979880,"tweetId":"179979880","gmtCreate":1626483945540,"gmtModify":1703760889757,"author":{"id":4088423044176710,"idStr":"4088423044176710","authorId":4088423044176710,"authorIdStr":"4088423044176710","name":"披着牛皮的雷熊","avatar":"https://static.tigerbbs.com/cf21af481bf46a359c6aa7128b04788a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":15,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>?</p></body></html>","htmlText":"<html><head></head><body><p>?</p></body></html>","text":"?","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/179979880","repostId":2152668878,"repostType":2,"repost":{"id":"2152668878","kind":"news","pubTimestamp":1626458887,"share":"https://ttm.financial/m/news/2152668878?lang=en_US&edition=fundamental","pubTime":"2021-07-17 02:08","market":"us","language":"zh","title":"American COVID-19 vaccine manufacturer Moderna successfully entered the bid, and its stock price rose nearly 9% during the session","url":"https://stock-news.laohu8.com/highlight/detail?id=2152668878","media":"腾讯美股","summary":"截止发稿，Moderna股价周五早盘大涨近9%，至每股283美元，创下历史新高，这将使该股今年迄今的涨幅扩大至165%左右，市值约为1120亿美元。此前，部分分析人士曾对Moderna的股价飙升表示担忧。此前，Moderna在5月6日公布了强于预期的第一季度每股收益2.84美元，营收增至19亿美元。Moderna当时表示，在一项针对12至17岁青少年的研究中，该公司的新冠疫苗100%有效。Moderna透露，其针对青少年的新冠疫苗2、3期研究覆盖了3732名年龄在12至18岁以下的受试者。","content":"<p><html><body><article><a href=\"https://laohu8.com/S/00700\">Tencent</a>Securities July 17 news, American COVID-19 vaccine manufacturer Moderna will successfully include next week<span>S&P 500 Index</span>, this is since the end of last year<a href=\"https://laohu8.com/S/TSLA\">Tesla</a>One of the most noteworthy constituent corrections since joining the benchmark index. Boosted by the news, the company's shares surged to record highs on Friday.</p><p><img src=\"http://inews.gtimg.com/newsapp_match/0/13774978940/0\"/>Following the US in December last year<a href=\"https://laohu8.com/S/ALXN\">Yalexiong Pharmaceutical</a>Alexion Pharmaceuticals By the UK<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>After the $39 billion acquisition of (AstraZeneca), Moderna will also replace the former's position in the world's most watched index. After experiencing a year-to-date gain of more than 150%, Moderna's market cap has now reached more than $100 billion.</p><p>As of press time, Moderna's stock price rose nearly 9% in early trading on Friday to $283 per share, a record high, which will expand the stock's year-to-date gains to about 165%, with a market value of about $112 billion.</p><p>Previously, some analysts had expressed concern about the surge in Moderna's stock price. But<a href=\"https://laohu8.com/S/JEF\">Jefferies</a>Analyst Michael Yee said in an email that Moderna continues to be driven by momentum, with recent findings \"clearly showing that their vaccines effectively cover mutated viruses.\"</p><p>In fact, before Moderna successfully developed COVID-19 vaccine, it was an unknown start-up pharmaceutical company, but it became famous after passing the emergency use authorization of the US Food and Drug Administration.</p><p>Previously, Moderna reported a stronger-than-expected first quarter on May 6<span>EARNINGS PER</span>2.84, with revenue increasing to $1.9 billion. At the same time, the drugmaker also raised its full-year vaccine sales forecast for fiscal year 2021 to around $19.2 billion.</p><p>Moderna CEO Stéphane Bancel said in early May that Moderna's basic plan for 2021 is to produce 800 million doses of mRNA vaccines, which received emergency approval from the US FDA in December last year, with the goal of \"striving to produce nearly 1 billion doses of vaccines in 2021.\"</p><p>\"The feedback from governments around the world for demand for highly effective mRNA vaccines and COVID-19 vaccine boosters to deal with mutated viruses is'overwhelming '. We are now actively participating in 2022 (plans) discussions and with all governments that we currently supply (vaccines) for 2021.\"</p><p>Last month, Moderna formally requested emergency approval from the U.S. Food & Drug Administration (FDA) to use its coronavirus vaccine, allowing administering to teens in the coming months. This is also the following<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>After that, a second vaccine that proved effective in younger populations.</p><p>Moderna said at the time that its COVID-19 vaccine was 100% effective in a study of 12-to 17-year-olds. Moderna revealed that its COVID-19 vaccine Phase 2 and 3 studies for adolescents covered 3,732 subjects aged 12 to under 18 years old. The company said no cases of Novel Coronavirus were observed among participants who received two doses of the vaccine, while four cases were observed in the placebo group. The trial showed that the vaccine was 93% effective after one dose.</p><p>The drugmaker asked the FDA to issue an emergency use authorization (EUA) notice allowing its mRNA-1273 vaccine to be administered to children ages 12 to 18.</p><p>In addition to this, Moderna made a similar request to European health authorities earlier this week, saying that late-stage data from its TeenCOVE study \"met the primary immunogenicity endpoint, successfully linking the immune response to adult vaccines in 2,500 participants\" with a vaccination efficiency of 100%.</p><p>In this regard, Marco Cavaleri, director of the European Medicines Agency EMA, said that the agency's expert committee is currently evaluating Moderna's application to expand the use of its COVID-19 vaccine to children aged 12 to 17. He said it was \"expected that the committee would come to a conclusion by the end of next week\". (Drew)</p><p></article></body></html></p>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>American COVID-19 vaccine manufacturer Moderna successfully entered the bid, and its stock price rose nearly 9% during the session</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmerican COVID-19 vaccine manufacturer Moderna successfully entered the bid, and its stock price rose nearly 9% during the session\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">腾讯美股</strong><span class=\"h-time small\">2021-07-17 02:08</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><article><a href=\"https://laohu8.com/S/00700\">Tencent</a>Securities July 17 news, American COVID-19 vaccine manufacturer Moderna will successfully include next week<span>S&P 500 Index</span>, this is since the end of last year<a href=\"https://laohu8.com/S/TSLA\">Tesla</a>One of the most noteworthy constituent corrections since joining the benchmark index. Boosted by the news, the company's shares surged to record highs on Friday.</p><p><img src=\"http://inews.gtimg.com/newsapp_match/0/13774978940/0\"/>Following the US in December last year<a href=\"https://laohu8.com/S/ALXN\">Yalexiong Pharmaceutical</a>Alexion Pharmaceuticals By the UK<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>After the $39 billion acquisition of (AstraZeneca), Moderna will also replace the former's position in the world's most watched index. After experiencing a year-to-date gain of more than 150%, Moderna's market cap has now reached more than $100 billion.</p><p>As of press time, Moderna's stock price rose nearly 9% in early trading on Friday to $283 per share, a record high, which will expand the stock's year-to-date gains to about 165%, with a market value of about $112 billion.</p><p>Previously, some analysts had expressed concern about the surge in Moderna's stock price. But<a href=\"https://laohu8.com/S/JEF\">Jefferies</a>Analyst Michael Yee said in an email that Moderna continues to be driven by momentum, with recent findings \"clearly showing that their vaccines effectively cover mutated viruses.\"</p><p>In fact, before Moderna successfully developed COVID-19 vaccine, it was an unknown start-up pharmaceutical company, but it became famous after passing the emergency use authorization of the US Food and Drug Administration.</p><p>Previously, Moderna reported a stronger-than-expected first quarter on May 6<span>EARNINGS PER</span>2.84, with revenue increasing to $1.9 billion. At the same time, the drugmaker also raised its full-year vaccine sales forecast for fiscal year 2021 to around $19.2 billion.</p><p>Moderna CEO Stéphane Bancel said in early May that Moderna's basic plan for 2021 is to produce 800 million doses of mRNA vaccines, which received emergency approval from the US FDA in December last year, with the goal of \"striving to produce nearly 1 billion doses of vaccines in 2021.\"</p><p>\"The feedback from governments around the world for demand for highly effective mRNA vaccines and COVID-19 vaccine boosters to deal with mutated viruses is'overwhelming '. We are now actively participating in 2022 (plans) discussions and with all governments that we currently supply (vaccines) for 2021.\"</p><p>Last month, Moderna formally requested emergency approval from the U.S. Food & Drug Administration (FDA) to use its coronavirus vaccine, allowing administering to teens in the coming months. This is also the following<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>After that, a second vaccine that proved effective in younger populations.</p><p>Moderna said at the time that its COVID-19 vaccine was 100% effective in a study of 12-to 17-year-olds. Moderna revealed that its COVID-19 vaccine Phase 2 and 3 studies for adolescents covered 3,732 subjects aged 12 to under 18 years old. The company said no cases of Novel Coronavirus were observed among participants who received two doses of the vaccine, while four cases were observed in the placebo group. The trial showed that the vaccine was 93% effective after one dose.</p><p>The drugmaker asked the FDA to issue an emergency use authorization (EUA) notice allowing its mRNA-1273 vaccine to be administered to children ages 12 to 18.</p><p>In addition to this, Moderna made a similar request to European health authorities earlier this week, saying that late-stage data from its TeenCOVE study \"met the primary immunogenicity endpoint, successfully linking the immune response to adult vaccines in 2,500 participants\" with a vaccination efficiency of 100%.</p><p>In this regard, Marco Cavaleri, director of the European Medicines Agency EMA, said that the agency's expert committee is currently evaluating Moderna's application to expand the use of its COVID-19 vaccine to children aged 12 to 17. He said it was \"expected that the committee would come to a conclusion by the end of next week\". (Drew)</p><p></article></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2021071702104079d40a73&s=b\">腾讯美股</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6e474d690ea02c536f0fd4c03fc3ddef","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2021071702104079d40a73&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2152668878","content_text":"腾讯证券7月17日讯，美国新冠疫苗制造商Moderna下周将成功纳入标准普尔500指数，这是自去年底特斯拉加入该基准指数以来最值得关注的成分股调整之一。受此消息提振，该公司股价在周五飙升至创纪录新高。继去年12月美国亚力兄制药（Alexion Pharmaceuticals）被英国阿斯利康（AstraZeneca）以390亿美元收购后，Moderna也将取代前者在全球最受关注的指数中的地位。在经历了年初至今超过150%的涨幅后，Moderna的市值如今已经达到了超过1000亿美元。截止发稿，Moderna股价周五早盘大涨近9%，至每股283美元，创下历史新高，这将使该股今年迄今的涨幅扩大至165%左右，市值约为1120亿美元。此前，部分分析人士曾对Moderna的股价飙升表示担忧。但杰富瑞分析师Michael Yee在一封电子邮件中表示，Moderna继续受到动力的驱动，最近的研究结果“清楚地显示出他们的疫苗能有效覆盖变异病毒”。事实上，在Moderna成功研发新冠疫苗前还是一家不为人知的新创药厂，但在通过美国食品药品监督管理局的紧急使用授权后名声大噪。此前，Moderna在5月6日公布了强于预期的第一季度每股收益2.84美元，营收增至19亿美元。同时，这家制药商还将2021财年全年疫苗销售预期上调至192亿美元左右。Moderna公司首席执行官斯特凡内·班塞尔（Stéphane Bancel）在5月初表示，Moderna在2021年的基本计划是生产8亿剂mRNA疫苗（Messenger RNA vaccines），该疫苗于去年12月获得美国FDA的紧急批准，目标则是“努力在2021年生产近10亿剂疫苗”。“世界各国政府对高效mRNA疫苗和新冠疫苗增强剂以应对变异病毒的需求反馈是‘压倒性的’。我们现在正积极参与2022年（计划）的讨论，并与我们目前为2021年供应（疫苗）的所有政府达成协议。”上个月，Moderna正式要求美国食品和药物管理局（U.S.Food&Drug Administration，FDA）紧急批准使用其冠状病毒疫苗，允许在未来几个月内向青少年接种。这也是继辉瑞之后，第二种在较年轻人群中被证明有效的疫苗。Moderna当时表示，在一项针对12至17岁青少年的研究中，该公司的新冠疫苗100%有效。Moderna透露，其针对青少年的新冠疫苗2、3期研究覆盖了3732名年龄在12至18岁以下的受试者。该公司称，在接受两剂疫苗的参与者中没有观察到新冠病毒病例，而在安慰剂组观察到4例病例。试验显示，注射该疫苗一剂后的有效性为93%。这家制药商要求FDA发布紧急使用授权（EUA）通知，允许将其mRNA-1273疫苗给12岁至18岁的儿童接种。除此之外，Moderna本周早些时候还向欧洲卫生当局提出了类似的请求，称其TeenCOVE研究的后期数据“达到了主要的免疫原性终点，在2500名参与者中成功地将免疫反应与成人疫苗连接起来”，疫苗接种效率为100%。对此，欧洲药品管理局EMA主任卡瓦莱里（Marco Cavaleri）表示，该机构的专家委员会目前正在评估Moderna将其新冠疫苗的使用范围扩大到12至17岁儿童的申请。他表示，“预计委员会将在下周末前得出结论”。（德鲁）","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2356,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}